Loading...
XKRX003220
Market cap206mUSD
Dec 30, Last price  
14,250.00KRW
1D
1.86%
1Q
-2.80%
Jan 2017
-9.78%
Name

Daewon Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:003220 chart
P/E
12.77
P/S
0.58
EPS
1,115.87
Div Yield, %
2.40%
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
12.95%
Revenues
526.95b
+10.04%
74,356,701,00090,659,340,000115,930,546,000144,696,109,000138,874,712,510138,168,464,960158,878,874,390181,984,511,140216,187,082,890240,722,373,520265,462,478,270286,652,511,070317,827,566,520308,501,015,860354,176,435,160478,884,656,360526,952,045,064
Net income
23.92b
-25.13%
7,819,323,0007,673,313,0009,761,816,00011,845,725,0009,436,354,0009,614,763,58012,320,944,75015,728,543,41017,694,916,95020,241,973,32010,742,011,29023,744,481,65027,288,953,78017,640,388,7006,988,825,61031,944,350,70023,916,930,918
CFO
51.73b
+55.24%
4,870,670,00011,827,404,00010,533,572,00016,782,211,00017,932,732,18013,827,655,89012,320,481,90017,447,350,53025,816,897,80020,791,924,5804,265,009,49040,032,139,06030,970,630,74024,951,403,57022,413,390,64033,325,991,99051,734,342,120
Dividend
Dec 27, 2023300 KRW/sh
Earnings
Mar 12, 2025

Profile

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells medicine and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis uses. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 45 countries primarily in Asia, Central and South America, the Middle East, etc. The company was founded in 1958 and is headquartered in Seoul, South Korea.
URL
https://www.daewonpharm.com/main/index.jsp
IPO date
Dec 15, 1999
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
526,952,045
10.04%
478,884,656
35.21%
Cost of revenue
394,361,883
360,031,026
Unusual Expense (Income)
NOPBT
132,590,162
118,853,630
NOPBT Margin
25.16%
24.82%
Operating Taxes
2,366,929
8,064,849
Tax Rate
1.79%
6.79%
NOPAT
130,223,233
110,788,782
Net income
23,916,931
-25.13%
31,944,351
357.08%
Dividends
(7,339,684)
(4,120,088)
Dividend yield
2.16%
1.00%
Proceeds from repurchase of equity
106,645
(6,182,326)
BB yield
-0.03%
1.51%
Debt
Debt current
110,577,206
63,396,226
Long-term debt
37,493,560
55,385,357
Deferred revenue
(11,018,244)
Other long-term liabilities
25,570,902
23,558,340
Net debt
28,906,749
55,368,588
Cash flow
Cash from operating activities
51,734,342
33,325,992
CAPEX
(21,936,329)
(13,365,129)
Cash from investing activities
(69,947,317)
(27,688,000)
Cash from financing activities
19,513,108
(20,410,542)
FCF
114,937,174
98,231,062
Balance
Cash
30,030,112
47,005,631
Long term investments
89,133,905
16,407,364
Excess cash
92,816,414
39,468,762
Stockholders' equity
264,950,788
448,759,588
Invested Capital
343,068,651
329,541,043
ROIC
38.72%
34.73%
ROCE
30.42%
31.27%
EV
Common stock shares outstanding
21,660
21,876
Price
15,660.00
-16.48%
18,750.00
15.99%
Market cap
339,197,323
-17.30%
410,166,750
19.58%
EV
366,169,606
463,353,312
EBITDA
150,150,876
138,221,631
EV/EBITDA
2.44
3.35
Interest
4,614,224
3,682,942
Interest/NOPBT
3.48%
3.10%